Journals / Sakarya Tıp Dergisi / 2014 / Cilt: 4 - Sayı: 4

Hypoxia-inducible factor-1: Physiological and Pathological Response to Hypoxia of Cell

Hipoksiyle İndüklenen Faktör-1: Hücrenin Hipoksiye Fizyolojik ve Patolojik Cevabı

Pages
171–177
Publication Date
2014-12-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overexpression of HIF-1 is determined in various cancer events and targeting HIF-1 is thought to be new approach in cancer treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hypoxia-inducible factor 1 (HIF-1) which has a critical role in the homeostasis of oxygen, is a transcriptional regulator of metabolic processes such as angiogenesis, erythropoiesis, iron metabolism and glucose metabolism.
📊
Key Findings & Data:HIF-1 is a heterodimeric protein consists of HIF-1α (homologues HIF-2α and HIF-2α) that involved in the regulation of oxygen and HIF-1β subunits that situated in the nucleus.
💡
Conclusion & Impact:Overexpression of HIF-1 is determined in various cancer events and targeting HIF-1 is thought to be new approach in cancer treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:HIF-1 · VHL · kanser

Abstract

Hypoxia-inducible factor 1 (HIF-1) which has a critical role in the homeostasis of oxygen, is a transcriptional regulator of metabolic processes such as angiogenesis, erythropoiesis, iron metabolism and glucose metabolism. It is also essential for the regulation of key physiological systems in the process of fetal and postnatal life. HIF-1 is a heterodimeric protein consists of HIF-1α (homologues HIF-2α and HIF-2α) that involved in the regulation of oxygen and HIF-1β subunits that situated in the nucleus. Stability and activity of HIF-1α subunit is provided with post-transcriptional modification such as hydroxylation, ubiquitination, acetylation and phosphorylation. In normoxia, this regulation that starting with two proline hydroxylation and lysine acetylation which are located in region HIF-1α oxygen-dependent degradation (ODD), is carried out with a tumor suppressor gene von Hippel-Lindau protein (pVHL) and E3 ligase complex by the ubiquitin-proteasome pathway. In hypoxic conditions, HIF-1α subunits that are not hydroxylation becomes stable and switches nucleus by activating with coactivators such as cAMP, protein/p300. Combining with HIF-1β subunit regulates the expression of genes in response to hypoxia. Overexpression of HIF-1 is determined in various cancer events and targeting HIF-1 is thought to be new approach in cancer treatment.

Özet

Oksijen homeostazında kritik bir rol oynayan hipoksiyle indüklenen faktör-1 (HIF-1); anjiyogenezis, eritropoezis, demir metabolizması ve glukoz metabolizması gibi metabolik süreçlerin transkripsiyonel regülatörüdür. Ayrıca fetal ve posnatal hayat sürecinde anahtar fizyolojik sistemlerin düzenlenmesi için gereklidir. HIF-1 heterodimerik bir protein olup oksijen regülasyonunda rol alan HIF-1α (homologları HIF-2α ve HIF-3α) ve nükleusta bulunan HIF-1β alt ünitelerinden oluşmaktadır. HIF-1'in α alt ünitesinin stabilitesi ve aktivitesi hidroksilasyon, ubikütinasyon, asetilasyon ve fosforilasyon gibi transkripsiyon sonrası modifikasyonlarla sağlanmaktadır. Normokside, HIF1-α'nın oksijen-bağımlı degradasyon (ODD) bölgesinde yer alan iki prolinin hidroksilasyonu ve bir lizinin asetilasyonuyla başlayan bu regülasyon bir tümör baskılayıcı gen olan von Hippel-Lindau proteini (pVHL) ile E3 ligaz kompleksi tarafından ubikütin-proteazom yolu ile gerçekleştirilmektedir. Hipoksik koşullarda, hidroksillenemeyen HIF-1α alt ünitesi stabil hale gelir ve cAMP, protein/p300 gibi koaktivatörler ile etkinleşerek nükleusa geçer. HIF-1β alt ünitesi ile birleşerek hipoksiye cevap genlerinin ekspresyonunu regüle eder. HIF-1'in aşırı ekspresyonu çeşitli kanser olgularında saptanmış ve HIF-1'in hedeflenmesinin kanser tedavisinde yeni bir yaklaşım olabileceği düşünülmüştür.

🔖

Cite This Article

DEMİREL, S. H., ÇETİNKAYA, S. (2014). Hypoxia-inducible factor-1: Physiological and Pathological Response to Hypoxia of Cell. Sakarya Tıp Dergisi, Cilt: 4 - Sayı: 4, 171–177. https://ajindex.com/articles/261776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Avni R, Cohen B, Neeman M. Hypoxic stres and cancer: Imaging the axis of evilin tumor metastasis. NMR Biomed 2011; 24: 569-581.
  2. Bahadori B, Uitz E, Mayer A, Harauer J, Dam K, Truschnig-Wilders M, Pilger E, Renner W. Polymorphisms of the hypoxia-inducible factor 1 gene peripheral artery disease. Vascular Medicine 2010; 15(5): 371-374.
  3. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl- hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 2003; 22: 4082-4090.
  4. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 1337-1340.
  5. Brusselmans K, Bono F, Maxwell P, Dor Y, Dewerchin M, Collen D, Herbert JM, Carmeliet P. Hypoxia-inducible factor 2-α (HIF-2α) is involved in the apoptotic response to hypoglycemia but not to hypoxia. J Biol Chem 2001; 276: 39192-39196.
  6. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-9525.
  7. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49: 507-521.
  8. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24: 68–72.
  9. Domene C, Illingworth CJR. Effects of point mutations in pVHL on the binding of HIF-1α. Proteins 2012; 80: 733-746.
  10. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakola P, Barstead R, Hodgkin PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107: 43-54.
  11. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-3918.
  12. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. Thrombin activates the hypoxia- inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res 2001; 89: 47-54. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
  13. Hes FJ, Höppener WM, Luijt RB, Lips CJM. Von Hippel-Lindau Disease. Hereditary Cancer Clinical Practice 2005; 3(4): 171-178.
  14. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW,